Only two days after Bridgebio Pharma Inc. impressed investors with data from BBP-418 in limb-girdle muscular dystrophy type ...

Leading advances in cancer research, the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ...

With a modest $7 million up front but an ultimate payout potentially topping $1 billion on the line, Modex Therapeutics Inc.

Medline Inc. filed a public S1 with the SEC Oct. 28, moving the IPO first signaled in December 2024 closer to reality. The Northfield, Ill.-based medical supply distributor did not disclose the number ...

Australian scientists have developed a simpler, less invasive way to detect Alzheimer’s disease that could make it easier for ...

Shooting for further proof of durable, drug-free, disease-free remission with a single dose of KYV-101 in generalized ...

Zag Bio Inc. came out of stealth mode with $80 million in funding so far, including a recently closed series A financing, to ...

Qyuns Therapeutics Co. Ltd. has entered into a collaboration and license agreement with F. Hoffmann-La Roche Ltd. granting ...

Exousia Pro Inc.’s subsidiary, Exousia AI, has received orphan drug designation from the FDA for its exosome-based treatment ...

CDR-609 is a T-cell engager therapeutic from CDR-Life Inc. that targets Leucine-rich repeat-containing G protein-coupled ...

The DeGregorio Family Foundation, with support from the Esophageal Cancer Awareness Association, has awarded an additional ...

Various derivatives of α-D-tocopherol (vitamin E) have shown antitumor potential by inhibiting metabolic processes in ...